首页> 美国卫生研究院文献>Frontiers in Psychiatry >Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation
【2h】

Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation

机译:莫达非尼和d-苯异丙胺的组合治疗可卡因依赖症的初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction. We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. >Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200 mg plus d-amphetamine 30 mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. >Results: Retention rates did not differ between groups and were generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups. The study medications were generally well-tolerated with few adverse effects, yet rates of adherence were suboptimal (≤80%). >Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.
机译:>背景:两种兴奋剂,莫达非尼和d-苯异丙胺,单独测试时,显示出可卡因成瘾的安全性和有效性。我们假设低剂量的莫达非尼和d-苯丙胺的组合与减少每种药物或安慰剂的较高剂量相比,在减少可卡因的使用方面具有相同或更大的益处。 >方法:十六周随机,平行分组设计,四个治疗组比较安慰剂与莫达非尼400μmg; d-苯丙胺60毫克;莫达非尼200微克加d-苯异丙胺30微克。在接受第一剂研究药物的73名参与者的样本中分析了主要结局变量,保留和可卡因使用情况。 >结果:两组间的保留率没有差异,通常较低,在第12周时仍保留40%的治疗,在第16周时仍保留20%的治疗。趋势是接受莫达非尼和d-苯异丙胺的组合的可卡因使用量随时间增加的情况,而贝叶斯获益的机率也较低(33%)。在仅安慰剂和d-苯异丙胺组中观察到相对较好的可卡因结果。研究药物通常耐受性良好,几乎没有不良反应,但是依从率次佳(≤80%)。 >结论:这项初步调查的数据未能为开展这项针对可卡因依赖性药物的双重激动剂药物联合研究的大规模研究提供证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号